Vendor Intelligence Report: Baoju Chemical

Published 3 Jul 2026. 26-page investigative report on who is behind Baoju Chemical: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 18 Finnrick lab tests, Baoju Chemical records 12 pass / 6 fail, an overall pass rate of 67%. The signal is uneven: Retatrutide is the clear strength, Tirzepatide is a lot-verification case, and BPC-157 is the weak link. Ratings also fall under stricter grading, so a pass is a quality-control signal, not proof of GMP manufacture, sterility, or clinical safety.

The corporate record is less clean than the Retatrutide result. Baoju presents a Shanghai supplier identity with long-history, large-factory, and certification language, but the independently observable web footprint concentrates in 2024 onward. Third-party profiles, a Global Sources veracity warning, blocked Chinese registry checks, and a shared email-routing domain leave age, scale, and legal traceability unresolved.

Operationally, Baoju has moved toward an inquiry-led storefront while catalog traces remain in the sitemap. The report maps the primary site, an offline secondary domain, @noraxeary social promotion, Lucy/Alisa/Lydia sales personas, and a ZZTAITech storefront sharing peptide categories and a Lucy bridge. That does not prove fraud, but it raises channel-authentication, lot-matching, and dispute-recovery risk.

For buyers, the report is a split decision rather than a blanket verdict: Baoju is a stronger candidate for Retatrutide than for BPC-157. The question becomes whether the exact channel, lot, COA, payment route, and import exposure can survive verification before funds move.

Inside the full report:

  • Appendix A per-product pass/fail data and methodology-divergence charts for all 3 tested products
  • Timeline of domain registrations, certificate records, archive captures, and public-profile claims
  • Corporate-identity comparison covering Global Sources, LookChem, Shanghai address, staffing, factory, and certification claims
  • Network map of baojuchemical.com, baojuchem.com, baojuxcl.com, hbxiaowo.com, zztaitech.com, @noraxeary, and sales personas
  • Catalog-risk review spanning peptides, hormone-adjacent products, DNP, insulin, EPO, botulinum toxin, and anabolic categories
  • Payment and import-risk analysis covering TT, Western Union, Bitcoin discounting, and CBP peptide-seizure context

Risk assessment

  • Misrepresented corporate history and scale claims — high: Global Sources long-history/staff/factory claims conflict with LookChem’s 2024 establishment signal and late-2024 domain, archive, and certificate records.
  • Operational and entity opacity — high: Inquiry-led storefront, Shanghai-versus-Henan signals, an offline secondary domain, Global Sources veracity warning, and blocked Chinese registry checks limit buyer traceability.
  • High-risk product catalog mix — high: Captured Baoju/related-profile materials include DNP, insulin, EPO, botulinum toxin, and anabolic/controlled categories alongside injectable peptides.
  • BPC-157 quality risk — high: BPC-157 is fail-heavy in Finnrick data: 6 tests (1 pass / 5 fail), 37.23%, materially weaker than Baoju’s Retatrutide record.
  • Tirzepatide lot-verification risk — medium: Tirzepatide has 4 Finnrick tests (3 pass / 1 fail), 78.53%; usable only with current lot-level third-party verification.
  • Channel-authenticity and brand-confusion risk — medium: Multiple related domains and Telegram/WhatsApp personas were observed, with no captured official-channel list, authorized-reseller list, anti-counterfeit system, or signed COA portal.
  • Non-reversible payment risk — medium: Global Sources lists TT/Western Union and zztaitech advertises Bitcoin discounts, limiting chargeback or dispute leverage.
  • US import-seizure and delivery-disruption risk — medium: CBP’s March 2026 peptide seizure involved Chinese shipments, mis-manifesting, and Baoju-catalog products; not Baoju-specific but directly route/category relevant.